---
title: "VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296932909.md"
description: "VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase"
datetime: "2026-08-25T15:01:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296932909.md)
  - [en](https://longbridge.com/en/news/296932909.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296932909.md)
generator: "portal-rs"
---

# VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase


### Related Stocks

- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)

## Related News & Research

- [VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision](https://longbridge.com/en/news/296815081.md)
- [VERAXA Biotech (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development](https://longbridge.com/en/news/292516474.md)
- [Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference | VNRX Stock News](https://longbridge.com/en/news/298594142.md)
- [ALXO: Biomarker-driven CD47 and novel EGFR ADC programs show promise for hard-to-treat cancers](https://longbridge.com/en/news/298621322.md)
- [VolitionRx presents early stage I solid cancer detection data for Capture-Seq at ESMO MAP conference](https://longbridge.com/en/news/298592775.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**